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ABSTRACT
Gefitinib, erlotinib or afatinib are the current treatment for non-small-cell lung cancer 
(NSCLC) harboring an activating mutation of the epidermal growth factor receptor (EGFR), 
but less than 5% of patients achieve a complete response and the median progression-
free survival is no longer than 12 months. Early adaptive resistance can occur as soon 
as two hours after starting treatment by activating signal transducer and activation of 
transcription 3 (STAT3) signaling. We investigated the activation of STAT3 in a panel of 
gefitinib-sensitive EGFR mutant cell lines, and gefitinib-resistant PC9 cell lines developed 
in our laboratory. Afatinib has great activity in gefitinib-sensitive as well as in gefitinib-
resistant EGFR mutant NSCLC cell lines. However, afatinib therapy causes phosphorylation 
of STAT3 tyrosine 705 (pSTAT3Tyr705) and elevation of STAT3 and RANTES mRNA levels. 
The combination of afatinib with TPCA-1 (a STAT3 inhibitor) ablated pSTAT3Tyr705 and 
down-regulated STAT3 and RANTES mRNA levels with significant growth inhibitory effect 
in both gefitinib-sensitive and gefitinib-resistant EGFR mutant NSCLC cell lines. Aldehyde 
dehydrogenase positive (ALDH+) cells were still observed with the combination at the 
time that Hairy and Enhancer of Split 1 (HES1) mRNA expression was elevated following 
therapy. Although the combination of afatinib with STAT3 inhibition cannot eliminate the 
potential problem of a remnant cancer stem cell population, it represents a substantial 
advantage and opportunity to further prolong progression free survival and probably 
could increase the response rate in comparison to the current standard of single therapy. 
INTRODUCTION
The epidermal growth factor receptor (EGFR)-
directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib 
and afatinib are approved therapies for non-small-cell lung 
cancer (NSCLC) harboring activating mutations in the 
EGFR kinase [1–3]. Gefitinib and erlotinib are reversible 
inhibitors that target the ATP-site of the kinase. In contrast, 
afatinib, a second generation irreversible epidermal growth 
factor family of receptor tyrosine kinases (ErbB) blocker, 
not only targets the ATP-site of the receptor, but also 
covalently binds to cysteine 797 (C797) of EGFR which 
allows prolonged inhibition of EGFR phosphorylation, 
even in the presence of a T790M secondary mutation [4]. 
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Afatinib also forms a covalent bond with the cysteine 
residue of HER2 (C805) and ErbB-4 (C803) and thus 
expands the inhibitory scope to the entire ErbB receptor 
family [5]. Resistance to EGFR TKIs arises rapidly and 
is attributed to the acquisition of a secondary T790M 
mutation between the ATP site of the receptor. Other 
common mechanisms of resistance have been reported, 
such as MET amplification and AXL overexpression [6]. In 
addition, selective irreversible inhibitors are highly active 
against the T790M mutant, but their efficacy can be limited 
by the acquired C797 mutation [7]. Intriguingly, in mouse 
models of EGFR (L858R/T790M/C797S) driven lung 
cancer, a new compound that targets selected drug-resistant 
EGFR but spares the wild-type receptor is effective in 
combination with cetuximab, an antibody that blocks EGFR 
dimerization and thus keeps the receptor in its inactive form 
[8]. Of interest is the fact that the combination of afatinib 
with 5-fluorouracil or pemetrexed inhibited the proliferation 
of NSCLC cells in vitro, whereas the combination of 
gefitinib with either of the two drugs was antagonistic. 
Afatinib induced downregulation of thymidylate synthase 
in the gefitinib-resistant NSCLC cells [9].
Afatinib was effective at lower concentrations 
than gefitinib in PC9 cells (derived from an untreated 
Japanese patient with lung adenocarcinoma carrying an 
exon 19 deletion [10]). Compared to gefitinib, afatinib 
also significantly prolonged survival of transgenic mice 
harboring an exon 19 deletion [11]. These findings mirror 
the results of the LUX-Lung 7 trial, where progression-
free survival (PFS) was longer with afatinib in comparison 
to gefitinib, with a hazard ratio of 0.73, p = 0.017 [12]. 
Analysis of PFS according to mutation type shows a PFS 
of 12.7 months for afatinib and 11 months for gefitinib 
(hazard ratio 0.76) [12]. The PFS curves separate more 
significantly with time, commencing at the median PFS 
[12]. In addition, the proportion of patients achieving an 
objective response with afatinib was higher than with 
gefitinib (70% and 56% respectively; ratio 1.87, p = 0.008) 
[12], but only 1% of patients treated with either afatinib or 
gefitinib obtained a complete response [12].
In PC9 or gefitinib-resistant PC9 cells, signal 
transducer and activator of transcription (STAT3) 
phosphorylation is not inhibited with gefitinib or afatinib, 
in comparison to the down-regulation of AKT and 
ERK phosphorylation [11]. EGFR mutant cells show 
early activation of BCL-2/BCL-XL survival signaling 
via activation of STAT3 [13]. By day nine of erlotinib 
inhibition in the HCC827 and PC9 cells, there were cell 
subpopulations (early survivors that evaded and survived 
erlotinib therapy). Tumor cells that survived up to 6–9 days 
of erlotinib treatment signaled independently of EGFR 
and MET with early STAT3 reactivation [13]. Blockage 
of STAT3 phosphorylation on the critical tyrosine residue 
705 (pSTAT3Tyr705) by niclosamide or TPCA-1 or depletion 
of STAT3 by RNA interference in HCC827 cells, reverts 
erlotinib resistance [14, 15]. Although STAT3 is activated 
by EGFR mutations [16, 17], other receptor and non-
receptor tyrosine kinases such as the interleukin-6 (IL-6)/
gp130 receptor can also stimulate STAT3 activation [18]. 
The levels of IL-6 mRNA were elevated in several EGFR 
mutant cell lines, including 11–18 and H1975. The mRNA 
levels of other IL-6 cytokines, such as oncostatin M, 
leukemia inhibitory factor, IL-11 and ciliary neurotropic 
factor were not detected [18]. Such findings show that 
IL-6 is secreted from these EGFR mutant cells and leads 
to activation of the gp130/JAK/STAT3 signaling pathway 
[18]. Introduction of activated EGFR into immortalized 
breast cells leads to carcinogenesis, IL-6 expression and 
STAT3 phosphorylation, which were all inhibited with a 
pan-JAK inhibitor or gp130 blockade [18]. Treatment of 
EGFR mutant cell lines with a pan-JAK inhibitor abrogated 
STAT3 and inhibited tumorigenesis while neither EGFR 
inhibitor nor dasatinib (Src kinase inhibitor) had any effect 
on STAT3 activity [18]. Afatinib was also shown to activate 
IL-6R/JAK1/STAT3 signaling pathway via interaction with 
fibroblasts and autocrine IL-6 secretion in H1975 and PC9 
gefitinib-resistant cells [19]. Blockade of IL-6R/JAK1 
significantly increased the sensitivity to afatinib [19]. Pre-
incubation of PC9 cells with erlotinib-treated conditioned 
media increased transcriptional activities of stress/immune 
response-associated factors, such as STAT3, interefron 
regulatory factor-1 and interferon gamma. Erlotinib directly 
increased pSTAT3Tyr705 in EGFR mutant cells, but did not 
affect STAT3 in EGFR wild type cells [20]. Lung cancer 
stem cells have elevated aldehyde dehydrogenase (ALDH) 
activity and erlotinib increased the ALDH stem-like cells 
in EGFR mutant cancer cells [21, 22]. 
We have shown that gefitinib or the third generation 
EGFR TKI osimertinib cannot inhibit STAT3 and YAP 
in EGFR mutant cell lines [23]. In the current study, we 
examined EGFR mutant cell lines, including gefitinib-
resistant PC9 cell lines, for the effect of afatinib in 
combination with TPCA-1, in inhibiting tumor growth 
proliferation and influencing signaling pathways that 
could down regulate STAT3. TPCA-1 (2-[(aminocarbonyl)
amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), is a 
non-peptidic small molecule inhibitor of the inhibitor of κB 
kinase-2 (IKK2) [24], and the Src homology 2-domain 
of STAT3 [15]. The afatinib with TPCA-1 combination 
effectively down-regulated pSTAT3Tyr705, with a substantial 
growth inhibitory effect in gefitinib sensitive cell lines, 
as well as those in gefitinib resistant cell lines, with or 
without the T790M mutation. 
RESULTS
Comparison of the sensitivity/resistance profile 
of EGFR mutant NSCLC cell lines to afatinib
We first assessed the activity of afatinib in 11 
human EGFR mutant NSCLC cell lines by using the 
MTT (tetrazolium-based semiautomated colorimetric 
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3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell proliferation assay (Figure 1 and Table 1). 
The activity of the covalent inhibitor afatinib was 
compared with the activity of the two reversible EGFR 
TKIs gefitinib and erlotinib. The gefitinib and erlotinib 
sensitive PC9 cell line that harbors the EGFR exon 19 
deletion was exquisitely sensitive to afatinib exposure 
(Figure 1 and Table 1). H3255 and 11–18 cells that carry 
the EGFR exon 21 L858R mutation were more sensitive 
to gefitinib compared to afatinib. EGFR is amplified 
approximately 11-fold in H3255 [25]. Among the three 
EGFR TKIs, afatinib had by far the highest molar potency 
in the H1975 cell line that carries the L858R/T790M 
double mutant EGFR. 
We have generated six EGFR TKI-resistant cell 
lines by treating EGFR TKI-sensitive PC9 cells with 
increasing concentrations of gefitinib (GR1-5) or erlotinib 
(ER). The half-maximal inhibitory concentration (IC50) 
for afatinib, gefitinib and erlotinib of parental PC9 cells 
was in the nanomolar range compared to 4–34 μM in the 
resistant cell lines. Sequencing analyses revealed that all 
six cell lines retained the EGFR exon 19 deletion (Table 
1), while the T790M mutation emerged in two of them 
(PC9-GR1 and PC9-GR4 at allelic fractions of 25 and 
38% respectively). Gene expression analysis by TaqMan 
based quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR) identified significant 
upregulation of AXL, a finding that was also confirmed 
by immunohistochemistry (IHC) and Western blotting in 
the PC9-GR2 cell line (data not shown).
Afatinib retained some inhibitory activity in the two 
PC9 gefitinib-resistant cells (PC9-GR1 and PC9-GR4) that 
have developed the T790M resistant mutation (Figure 1 
and Table 1). None of the EGFR TKIs (afatinib, gefitinib 
or erlotinib) was active in the rest of the PC9 gefitinib-
resistant clones, or in the PC9-ER cell line. Similarly, 
neither afatinib nor gefitinib were active in the H1650 cell 
line, which harbors the EGFR exon 19 deletion but has 
also a phosphatase and tensin homologue (PTEN) deletion 
[26] and particularly displays low expression of the BH3-
only protein, Bcl-2 interacting mediator of cell death 
(BIM; also known as BCL2-like 11) [27, 28] (Figure 1 
and Table 1).
In vitro growth inhibition of EGFR mutant 
NSCLC cells treated with afatinib in 
combination with TPCA-1
Based on previously reported knowledge that 
STAT3 activation can limit the cellular response to 
EGFR TKI treatment [13, 15, 18, 20], we assessed the 
growth inhibitory effects of the combination of afatinib 
Figure 1: In vitro sensitivity to afatinib. Eleven cell lines with IC50 values represented in μM. Error bars indicate the standard error 
based on multiple experiments.
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plus TPCA-1 (STAT3 inhibitor) in EGFR mutant cell 
lines. We performed an MTT cell proliferation assay on 
EGFR TKI sensitive and resistant cells and we used the 
method of constant ratio drug combination proposed by 
Chou and Talalay [29] to determine synergy, additivity, or 
antagonism of afatinib plus TPCA-1. A 72-hour exposure 
to afatinib and TPCA-1 resulted in a clear synergism in 
PC9 cells as measured by the combination Index (CI) 
analysis, with a CI of 0.82 (Figure 2A). A clear synergism 
was also observed by adding TPCA-1 to afatinib in 11–18 
cells with a CI of 0.69 (Figure 2B). Of interest the 
synergism was also evident in two PC9 gefitinib-resistant 
cells. Specifically, in PC9-GR2 cells, that do not harbor 
the T790M mutation, the combination of afatinib (in the 
IC50 dose of 4 µM) and TPCA-1 was synergistic with 
a CI of 0.80 (Figure 2C). In the PC9-GR4 cell line, that 
harbors the T790M mutation, the combination of afatinib 
and TPCA-1 was highly synergistic with a CI of 0.45 as 
shown by the isobologram analysis and the representative 
curves in Figure 2D. An additive effect was observed with 
the combination of afatinib and TPCA-1 in the H1975 
cell line, with a CI close to one (CI = 0.92). These results 
indicate that combined treatment of EGFR mutant NSCLC 
cell lines with a STAT3 inhibitor and afatinib is associated 
with enhanced antitumor effect. 
STAT3 inhibition potentiates the effect of 
afatinib on downstream signaling pathways in 
EGFR mutant NSCLC cells 
We then tried to explore the molecular mechanism 
by which STAT3 inhibition with TPCA-1 enhances the 
efficacy of afatinib alone in EGFR mutant cell lines. To 
this scope, we first examined the phosphorylation status of 
EGFR, STAT3, AKT and ERK1/2 after afatinib treatment 
in the two afatinib-sensitive cell lines, PC9 and PC9-GR4 
and the afatinib resistant cell line PC9-GR2. Afatinib 
suppressed EGFR, AKT and ERK1/2 phosphorylation but 
increased pSTAT3Tyr705 in a dose-dependent manner in all 
the cell lines (Figure 3A–3C). PC9 cells showed increased 
STAT3 and RANTES (regulated upon activation, normal 
T-cell expressed and presumably secreted) mRNA levels 
following seven days of afatinib treatment as examined by 
qRT-PCR analysis (Figure 3D–3E). RANTES expression 
is dependent on a transcription factor complex of STAT3 
with NF-κB [30]. When afatinib was combined with 
TPCA-1 in the PC9 cell line, no increase in the mRNA 
expression of STAT3 or RANTES could be detected after 
seven days of treatment (Figure 4A–4B). Furthermore 
in the two PC9 gefitinib-resistant cells, PC9-GR2 and 
PC9-GR4, in which the double combination was highly 
synergistic, pSTAT3Tyr705 was clearly abrogated when 
TPCA-1 was added to afatinib (Figure 4C–4D).
Afatinib treatment increases the fraction of 
ALDH+ cells 
We then tested whether afatinib alone or in 
combination with TPCA-1 had an effect on the fraction 
and number of stem-like cells in the PC9 cell line. 
Cells were treated with DMSO or with 0.0015 μM and 
0.003 μM of afatinib. Equal numbers of cells were 
subjected to ALDH enzymatic activity assays with the 
ALDH positive (ALDH+) and ALDH negative (ALDH-) 
cells quantified using flow cyrometry. There was a dose-
dependent increase in the fraction of ALDH+ cells upon 
treatment with afatinib compared with DMSO treated 
cells (Figure 5A). Concomitant treatment with afatinib 
Table 1: Characterization of EGFR mutant NSCLC cell lines and sensitivity to afatinib, erlotinib 
and gefitinib
Cell lines EGFR status
IC50 (µM)
Afatinib Erlotinib Gefitinib
PC9 Del19 0.003 0.045 0.040
H3255 L858R 
(EGFR amplification)
0.0057 -- 0.002
PC9-GR1 Del19, T790M (25%) 0.323 4.828 11.140
PC9-GR2 Del19 4.082 25.055 21.735
PC9-GR3 Del19 5.457 33.743 15.752
PC9-GR4 Del19, T790M (38%) 0.452 3.842 6.271
PC9-GR5 Del19 2.062 21.840 18.125
PC9-ER Del19 5.176 28.598 14.356
11-18 L858R 1.256 -- 0.491
H1650
Del19 
(PTEN loss/low BIM expression)
1.759 -- 13.665
H1975 L858R/T790M 0.287 2.514 9.221
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and TPCA-1 eliminated much of the ALDH- population 
but the proportion of ALDH+ cells was not affected 
(Figure 5A). This observation indicates that the afatinib-
induced increase of ALDH+ cells is independent of STAT3 
modulation. The qRT-PCR analysis of Hairy and Enhancer 
of Split 1 (HES1), that functions in the maintenance of 
cancer stem cells, showed a significant increase after seven 
days of treatment with afatinib alone or in combination 
with TPCA-1 in PC9 cells (Figure 5B). 
DISCUSSION
Although EGFR TKIs induce a significant number 
of radiographic responses, almost no complete responses 
Figure 2: Effect of the double combination of afatinib and TPCA-1 in four EGFR mutant cell lines. PC9 (A), 11–18 (B), 
PC9-GR2 (C) and PC9-GR4 (D) cells were treated with serial dilutions of afatinib and TPCA-1 alone and with their double combination 
for 72 h. The cell viability was measured by MTT and the synergy between the drugs was determined using the Chou and Talalay method 
(Chou and Talalay plot or Fa plot). The dotted horizontal line at 1 indicates the line of additive effect. Effect (Fa) indicates the fractional 
inhibition for each combinational index (CI). To calculate drug concentration for each Fa point the drugs were mixed using constant ratios 
corresponding to 1/8, 1/4, 1/2, 5/8, 3/4, 7/8, 1, 1.5 and 3 of the individual IC50 values for each drug in PC9, 11–18, PC9-GR2 and PC9-GR4 
cells. The results represent the means of at least three independent experiments.
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are obtained and the median PFS does not exceed more 
than one year. Still no combinatory therapies based on 
EGFR TKIs have been approved for the treatment of 
EGFR mutant NSCLC patients in first line. As soon as 
EGFR mutations were discovered in NSCLC, they were 
associated with dramatic response to gefitinib [31, 32]. It 
was also noted that EGFR mutant lung cancer cell lines 
selectively activate AKT and STAT3 signaling pathways, 
promoting cell survival. Importantly, NSCLC cells 
expressing mutant EGFR underwent extensive apoptosis 
after treatment with pharmacological inhibitors of AKT 
(Ly294002) and STAT (AG490) signaling [33]. The goal 
of the present study was to investigate whether STAT3 is 
activated almost immediately after afatinib treatment by 
tyrosine phosphorylation in response to epidermal growth 
factor (EGF) and interleukin-6 (IL-6) [34], similar to what 
has been reported for erlotinib or gefitinib therapy [13, 20]. 
EGFR mutations activate ERK, AKT and STAT3 directly 
or through IL-6-JAK2 [18, 33, 35]. pSTAT3Tyr705 is induced 
two hours after erlotinib or gefitinib treatment [13, 15, 20]. 
An IL-6 mediated crosstalk between NF-κB and STAT3 
has been described in EGFR-mutant NSCLC cells [15]. We 
have recently shown that gefitinib or osimertinib treatment 
results in the activation of not only STAT3, but also Src-
YAP1 signaling, potentially operating downstream of IL-6, 
to promote cell survival and limit the initial response to 
EGFR TKI treatment in EGFR mutant lung cancer [23].
Our findings indicate that abrogating STAT3 
signaling is relevant in EGFR mutant cells, showing 
remarkable synergism when afatinib is combined with 
TPCA-1 (a STAT3 inhibitor) [15] in gefitinib-sensitive 
mutant EGFR cells (Figure 2A–2B), as well as in gefitinib-
resistant PC9 cells, that are resistant to single afatinib 
treatment, particularly in PC9-GR2 (harboring AXL 
overexpression) (Figure 1 and Figure 2C). This observation 
is intriguing since we previously reported that increased 
AXL expression was a relevant mechanism of acquired 
resistance to EGFR TKIs [36]. The fact that the IC50 for 
afatinib in PC9-GR4 (38% allelic fraction of T790M) 
was in sub-nanomolar range with significant synergism 
in combination with TPCA-1 was quite noteworthy 
(Figure 2D). Although afatinib inhibits ERK and AKT 
signaling in PC9, PC9-GR2 and PC9-GR4, it does not 
abrogate pSTAT3Tyr705 (Figure 3A–3C). A gradual increase 
in STAT3 and RANTES mRNA levels was observed after 
seven days of treatment (Figure 3D–3E). This finding is 
of utmost importance since STAT3 activation can result 
in increased concentration of un-phosphorylated STAT3, 
driving a second wave of gene expression, such as 
RANTES [37]. Other studies have shown that inhibition 
of STAT3 phosphorylation leads to down-regulation of 
RANTES mRNA levels. However, the combination of 
afatinib with TPCA-1 was highly synergistic in PC9-GR4 
cells, inhibiting pSTAT3Tyr705 and preventing up-regulation 
Figure 3: Effect of afatinib on signal transduction pathways. Protein lysates from the PC9 (A) PC9-GR2 (B) and PC9-GR4 
(C) cell lines treated with increasing doses of afatinib for 24 hours were collected and assessed by western blot analysis. STAT3 (D) and 
Rantes, (E) mRNA expression was measured using quantitative reverse transcription-PCR in PC9 cells that were treated with 0.003 μM of 
afatinib for seven days. Data were generated from a minimum of three replicates. β-actin was used to normalize gene expression. Data are 
presented as the means ± standard deviation; *P < 0.05.
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of STAT3 and RANTES mRNA levels (Figure 4). Finally 
we observed that afatinib increased the ALDH+ cell sub-
population (Figure 5A). Although in other studies ALDH+ 
are reduced with IL-6/JAK1/STAT3 signaling blockade 
[38], we did not observe any decrease of ALDH+ cells 
with the combination of afatinib and TPCA-1 (Figure 5B). 
ALDH+ cells are considered representative of cancer stem-
like cells [21] and are reported to be a consequence of 
crosstalk between EGFR and NOTCH signaling pathways 
in EGFR mutant tumors [22]. HES1 mRNA expression 
was elevated following therapy of PC9 cells with either 
afatinib or the combination of afatinib plus TPCA-1 
(Figure 5C).
Accumulated evidence indicates that the 
combination of EGFR TKI with STAT3 inhibitors could 
be of benefit and increase the anti-tumor activity of these 
agents. In addition to TPCA-1, several repurposed and 
clinically approved drugs are considered active STAT3 
inhibitors [39]. Clinical trials are warranted for the 
combination of afatinib plus STAT3 inhibitors. Figure 6 
shows our working model. Although combinatory therapy 
with STAT3 inhibitors represents only an initial step 
towards progress in the management of EGFR mutant 
lung cancer, compelling evidence indicates the need for 
a switch from monotherapy to combination therapy and 
illustrates how pre-clinical research could pave the way to 
implement such clinical trials. 
The incidence of the acquired EGFR T790M mutation 
is as prevalent in patients treated with afatinib as in patients 
treated with erlotinib or gefitinib [40]. Even though afatinib 
cannot clinically reverse T790M-mediated resistance, the 
evidence that afatinib inhibits cell proliferation in PC9-
Figure 4: Effect of afatinib plus TPCA-1 on signal transduction pathways. STAT3 (A) and Rantes, (B) mRNA expression were 
measured using quantitative reverse transcription-PCR in PC9 cells that were treated with 3.1M of afatinib and 2.5 μM of TPCA-1 for seven 
days. Data were generated from a minimum of three replicates. β-actin was used to normalize gene expression. Data are presented as the 
means± standard deviation; *P >0.05. Afatinib plus TPCA-1 inhibits phosphorylation of EGFR and STAT3 in a dose-dependent manner in 
PC9-GR2 (C) and PC9-GR4 (D) cells. Protein lysates from the PC9-GR2 and PC9-GR4 cell lines treated with increasing doses of afatinib 
and TPCA-1 for 24 hours were collected and assessed by western blot analysis.
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GR4 with T790M, as well as in PC9-GR2 with AXL 
overexpression is in line with its ability to delay emergence 
of resistance through this mechanism. Indeed, gene dosage 
of the T790M EGFR mutation seems to be important [41]. 
Evaluation of this combination is thus of interest and merits 
further investigation, especially now that we are on the 
verge of monitoring EGFR mutations in circulating DNA 
[17, 42]. The early detection of T790M in plasma could be 
of further assistance in EGFR mutant patients treated with 
afatinib in combination with STAT3 inhibitors. 
MATERIALS AND METHODS
Chemicals and reagents
EGFR inhibitors (erlotinib, gefitinib and afatinib) 
and TPCA-1 were purchased from Selleck Chemicals 
(Houston, TX, USA). Drugs were prepared in dimethyl 
sulfoxide (DMSO) at a concentration of 10–100mmol/L 
stock solutions and stored at –20 °C. Further dilutions 
were made in culture medium to final concentration before 
use. Phospho-EGFR (Tyr1068), phospho-STAT3 (Tyr705), 
phospho-ERK1/2 (Thr202/Tyr204) and β-actin antibodies 
were purchased from Cell Signaling Technology (Beverly, 
MA). The secondary antibodies Amersham ECL-anti-
rabbit IgG horseradish peroxidase-linked species-specific 
whole antibody and Amersham ECL-anti-mouse IgG 
peroxidase-linked whole antibody were purchased from 
GE Healthcare UK limited (Buckinghamshire, UK).
Cell lines
Human lung adenocarcinoma PC9 cells, harboring 
EGFR exon 19 deletion (E746-A750) were provided by F. 
Figure 5: Afatinib treatment of EGFR-mutant lung cancer cells increases the fraction of ALDH+ cells in a dose-
dependent manner. (A) PC9 cells were treated with DMSO, and 0.0015 μM and 0.003 μM of afatinib or 0.003 μM of afatinib plus 
2.5 μM of TPCA-1 for 7 days, and subjected to Aldefluor assay to detect the ALDH+ cells. A portion of the cells was preincubated with 
the ALDH inhibitor DEAB (+DEAB) to provide a gate (ALDH- cells) for flow cytometry. (B) HES1 mRNA expression were measured 
using quantitative reverse transcription-PCR in PC9 cells that were treated with 0.003 μM of afatinib or 0.003 μM of afatinib plus 2.5 μM 
of TPCA-1 for seven days. Data were generated from a minimum of three replicates. β-actin was used to normalize gene expression. Data 
are presented as the means ± standard deviation; *P < 0.05.
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Hoffmann-La Roche Ltd. with the authorization of Dr. 
Mayumi Ono (Kyushu University, Fukuoka, Japan). 
Human lung adenocarcinoma 11–18 and H3255 cells, 
harboring EGFR exon 21 L858R mutation, were provided 
by Dr. Mayumi Ono and Dr. Daniel Costa (Department 
of Medicine, Harvard Medical School, Boston, MA) 
respectively. Human lung adenocarcinoma H1975 cells, 
harboring both sensitizing L858R and resistant T790M 
mutation, were purchased from the American Type Culture 
Collection (ATCC). Human lung adenocarcinoma H1650 
cells, harboring EGFR exon 19 deletion (E746-A750) 
and PTEN loss, were purchased from the American 
Type Culture Collection (ATCC). We have generated six 
EGFR TKI-resistant cell lines by treating EGFR TKI-
sensitive PC9 cells with increasing concentrations of 
gefitinib (GR1-5) or erlotinib (ER). Sequencing analyses 
revealed that all six cell lines retained the EGFR exon 19 
deletion (Table 1), while the T790M mutation emerged 
in two (PC9-GR1 and PC9-GR4 at allelic fractions of 25 
and 38% respectively). All cell lines were maintained in 
RPMI (Roswell Park Memorial Institute medium) 1640 
supplemented with 1x penicillin/ streptomycin/ glutamine 
(Gibco) and 10% fetal bovine serum (FBS) (Gibco) in 
5% CO2, 37 °C cell culture incubator and were routinely 
evaluated for mycoplasma contamination. 
Cell viability assay
Cells were seeded on 96-well plates at the following 
densities: PC9 at 2 × 103, 11–18 at 3 × 103, H3255, PC9-
GR2, PC9-GR4 at 4 × 103 and H1975 at 6 × 103 and 
incubated for 24 hours. Next, the cells were treated with 
serial dilutions of the drugs administrated at doses typically 
corresponding to 1/8, 1/4, 1/2, 5/8, 3/4, 7/8, 1, 1.5 and 3 of 
the individual IC50 values. After 72 hours of incubation, 
0.275 mg/ml of MTT reagent (Sigma Aldrich) was added 
to the medium in the wells for 2 hours at 37°C, formazan 
crystals in viable cells were solubilized with 100 ml DMSO 
and spectrophotometrically quantified using a microplate 
reader (Varioskan Flash Thermo Electron) at 550 nm of 
absorbance. Fractional survival was then calculated by 
dividing the number of cells in drug-treated wells by the 
number of cells in control wells. Data of combined drug 
effects were subsequently analyzed by the Chou and 
Talalay method [29]. CI values < 1, =1 and > 1 indicated 
synergism, additive effect and antagonism, respectively. 
Gene expression analyses
RNA was isolated from the cell lines in accordance 
with a proprietary procedure (European patent number 
Figure 6: STAT3 activation and enrichment in ALDH+ cells in EGFR-mutant NSCLC. Activation of EGFR has been 
linked to the pro-survival signaling pathways, including AKT, STAT3 and RAF/MEK/ERK mitogen-activated protein kinase (MAPK). 
EGFR mutant lung cancer cells produce high IL6 levels, which subsequently activates the gp130/JAK/STAT3 pathway. Unphosphorylated-
STAT3 (U-STAT3), induced due to activation of the STAT3 in response to EGFR mutations or ligands such as IL-6, activates genes such 
as RANTES.
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EP1945764-B1) as previously described [43]. The primer 
and probe sets were designed using Primer Express 3.0 
Software (Applied Biosystems) according to their Ref Seq 
(http://www.ncbi.nlm.nih.gov/LocusLink). Specifically, 
sequences of the primer sets and the probes for 
amplification of the genes examined in the study were as 
follows: STAT3, forward primer, 5′-CACCTTCAGGATGT 
CCGGAA-3′, reverse primer, 5′-ATCCTGGAGATTCTCT 
ACCACTTTCA-3′, probe 5´-FAM AGAGTGCAGGATC 
TAGA-MGB 3′; RANTES, forward primer, 5′-CATC 
TGCCTCCCCATATTCCT-3′, reverse primer, 5′-AGTGGG 
CGGGCAATGTAG 3′, probe 5´-FAM ACACCACACCC 
TGCTG-MGB 3′; HES1, forward primer, 5′-GGACATT 
CTGGAAATGACAGTGAA-3′, reverse primer, 5′-CAG 
CACACTTGGGTCTGTGC-3′, probe 5´-FAM ATGAC 
GGCTGCGCTGA-MGB 3′; β-actin, forward primer, 5′- TG 
AGCGCGGCTACAGCTT-3′, reverse primer, 5′-TCCTT 
AATGTCACGCACGATTT-3′, probe 5´-FAM ACCACCA 
CGGCCGAGCGG TAMRA 3′. Quantification of gene 
expression was performed using the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems). 
Expression levels were calculated according to the 
comparative ΔΔCt method. Commercial RNA controls 
were used as calibrators (Liver and Lung; Stratagene, La 
Jolla, CA, USA). For each cell line, three independent 
experiments were performed.
Western blotting
Cells were washed with cold phosphate-buffered 
saline (PBS) and re-suspended in ice-cold radio-
immunoprecipitation assay (RIPA) buffer (20 mM Tris- 
hydrochloric acid in pH 7.5, 1% Nonidet P-40, 0.5% 
sodium deoxycholate, 150 mM sodium chloride, 1 mM 
ethylenediaminetetraacetic acid, 1 mM EGTA, 2.5 mM 
sodium pyrophosphate, 1 mM beta-glycerophosphate and 
1 mM sodium vanadate) containing protease inhibitor 
mixture. Following cell lysis and centrifugation at 
14000 × rpm for 10 min at 4°C, the resulting supernatant 
was collected as the total cell lysate. Briefly, the lysates 
containing 30 μg proteins were electrophoresed on 
10% SDS-polyacrylamide gel electrophoresis (Life 
Technologies) and transferred to polyvinylidene difluoride 
membranes (BIO-RAD laboratories). Membranes were 
blocked in Odyssey blocking buffer (LI-COR Biosciences). 
All target proteins were immunoblotted with appropriate 
primary and peroxidase conjugated secondary antibodies. 
Quimioluminiscence bands were detected with Bio-Rad 
ChemiDoc MP Imaging System.
Aldefluor assay and flow cytometry
The Aldefluor assay kit (Stem Cell Technologies, 
Vancouver, BC, Canada) was used to determine the profile 
of cells with high and low ALDH activity. The assay was 
performed according to manufacturer’s instructions, 
with certain modifications. Briefly, 2 × 106 cells were 
suspended in Aldefluor assay buffer and divided into 
two groups. One group was pretreated for 10 min with 
the ALDH-specific inhibitor diethylaminobenzaldehyde 
(DEAB) and then both groups were incubated with ALDH 
enzyme substrate BODIPY-aminoacetaldehyde for 30 min 
at 37°C. Cells were then centrifuged and re-suspended in 
a fresh Aldefluor assay buffer to remove the unutilized 
substrate. The fluorescence intensity of stained cells was 
analyzed using a FACS canto II (BD Biosciences) flow 
cytometer. For the analysis, DEAB-treated sample was 
used as a negative control. The ALDH activity of a sample 
was determined to be ‘high’ or ‘low’ based on fluorescence 
intensity above or below the threshold defined by the 
reaction with DEAB.
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